Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/29347
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- IOC - Artigos de Periódicos [12500]
Metadata
Mostrar registro completo
PORE FORMING CHANNELS AS A DRUG DELIVERY SYSTEM FOR PHOTODYNAMIC THERAPY IN CANCER ASSOCIATED WITH NANOSCINTILLATORS
sistema de administração de medicamentos
Câncer
terapia fotodinâmica
nanocintiladores
photodynamic therapy
nanoscintillators
Pore forming channels
drug delivery system
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Comunicação Celular. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Comunicação Celular. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Comunicação Celular. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Comunicação Celular. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Comunicação Celular. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Toxoplasmose. Rio de Janeiro, RJ. Brasil.
Resumo em Inglês
According to the World Health Organization (WHO), cancer is one of main causes
of death worldwide, with 8.2 million people dying from this disease in 2012. Because of
this, new forms of treatments or improvement of current treatments are crucial. In this
regard, Photodynamic therapy (PDT) has been used to successfully treat cancers that
can be easily accessed externally or by fibre-optic endoscopes, such as skin, bladder
and esophagus cancers. In addition, this therapy can used alongside radiotherapy
and chemotherapy in order to kill cancer cells. The main problem in implementing
PDT is penetration of visible light deeper than 10 mm in tissues, due to scattering
and absorption by tissue chromophores. Unfortunately, this excludes several internal
organs affected by cancer. Another issue in this regard is the use of a selective cancer
cell-photosensitizing compound. Nevertheless, several groups have recently developed
scintillation nanoparticles, which can be stimulated by X-rays, thereby making this
a possible solution for light production in deeper tissues. Alternative approaches
have also been developed, such as photosensitizer structure modifications and cell
membrane permeabilizing agents. In this context, certain channels lead to transitory
plasma membrane permeability changes, such as pannexin, connexin hemmichannels,
TRPV1-4 and P2X7, which allow for the non-selective passage of molecules up to 1,000
Da. Herein, we discuss the particular case of the P2X7 receptor-associated pore as a
drug delivery system for hydrophilic substances to be applied in PDT, which could also
be carried out with other channels. Methylene blue (MB) is a low cost dye used as a
prototype photosensitizer, approved for clinical use in several other clinical conditions,
as well as photodynamic therapy for fungi infections.
Palavras-chave
Canais formadores de porossistema de administração de medicamentos
Câncer
terapia fotodinâmica
nanocintiladores
Palavras-chave em inglês
cancerphotodynamic therapy
nanoscintillators
Pore forming channels
drug delivery system
Compartilhar